Background Assessment of the efficiency of interventions is paramount to achieving
equitable health-care systems. One key barrier to the widespread use of economic …

The study aims to empirically analyze the complex interrelationships between the digital
economy, consumption upgrading, and carbon emissions across 30 Chinese provinces from …

The cost-effectiveness of conventional population-based breast cancer screening strategies
(eg mammography) has been found controversial, while evidence shows that genetic testing …

Many health technology assessment committees have an explicit or implicit reference value
(often referred to as a 'threshold') below which new health technologies or interventions are …

Like most of the world, low-and middle-income countries have faced a growing demand for
new health technologies and higher budget constraints. It is necessary to have technical …

Introduction The willingness to pay per quality-adjusted life year gained (WTP/Q) is
commonly used to determine whether an intervention is cost-effective in health technology …

Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with
chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer …

Public payers around the world are increasingly using cost-effectiveness thresholds (CETs)
to assess the value-for-money of an intervention and make coverage decisions. However …

In the past two decades, most high-income countries have reduced their hospital bed
capacity. This could be a sign of increased efficiency but could also reflect a degradation in …

Objective We aimed to investigate the cost-effectiveness of nivolumab plus chemotherapy
and nivolumab plus ipilimumab versus chemotherapy in the first-line treatment for advanced …